About us
What we do
Our strategy
Market opportunity
Our team
Our history
Origins – Institute of Cancer Therapeutics (ICT) Bradford
Pipeline
Our products
For patients
Partnering
Our partnerships
Investors
Overview
Why invest?
Investment Case
IPO materials
Regulatory news
Results, Reports and Presentations
Research Notes
Email alerts
Share price and tools
Financial calendar
Shareholder information
Investor and Advisor contacts
AQSE Growth Market Rule 4.14
Corporate Governance
Company Contact Details
News & media
News
Press Coverage
Scientific Publications
Contact Us
Sustainability
Share price
INC 12.55 GBp
About us
What we do
Our strategy
Market opportunity
Our team
Board of Directors
Senior Management
Advisors and Founders
Our history
Origins – Institute of Cancer Therapeutics (ICT) Bradford
Pipeline
Our products
For patients
Partnering
Our partnerships
Investors
Overview
Why invest?
Investment Case
IPO materials
Regulatory news
Results, Reports and Presentations
Research Notes
Email alerts
Share price and tools
Share price chart
Detailed share price
Financial calendar
Shareholder information
Shareholder Information
AGM
GM
Analyst coverage
Investor and Advisor contacts
AQSE Growth Market Rule 4.14
Corporate Governance
Corporate Governance Report
Company Contact Details
News & media
News
Press Coverage
Scientific Publications
Contact Us
Sustainability
Latest from Incanthera
Home
News & media
Latest from Incanthera
Latest from Incanthera
2021
2020
2018
Archive
August 20th, 2014
ICT01 – patent granted in Japan
June 23rd, 2014
Company starts preclinical development of ICT03-Es5 agent
May 15th, 2014
Company secures IP protection in Japan for ICT01
April 20th, 2014
Company appoints new Chiarman
April 10th, 2014
ICT01 US Patent Granted
March 18th, 2014
Incanthera acquires Onco-NX Ltd
Prev
1
2
3
Next